The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; none of the 42 sources its claims cite is checked for support yet.
Delays in breast cancer presentation, diagnosis, and treatment in young women
Open accessAbstract
Background: Breast cancer (BC) in young patients is often identified at later stages, which can result in poor prognosis. It is important to investigate the factors influencing care delays and how delays affect outcomes. Methods: This study included women aged ≤40 years at diagnosis of stage 0–IV BC in the Young Women’s Breast Cancer Study enrolled between 2006 and 2016. Associations between patient and tumor factors and presentation delay (first symptom to provider visit, ≥90 days), diagnostic delay (presentation to diagnosis, ≥90 days), and treatment delay (diagnosis to treatment, ≥60 days) were estimated via logistic regression. Multivariable logistic models for delays were constructed via backward selection ( p ≤ .05 retained). Multivariable Cox proportional hazards models tested the association between delays and disease‐free survival (DFS) and overall survival (OS). Analyses were stratified by tumor subtype and stage. Results: Among 1071 women, there were 153 presentation, 120 diagnostic, and 228 treatment delays. In multivariable models, lower annual income was associated with higher odds of presentation delay, whereas pregnancy at diagnosis, family history of BC, and triple‐negative (TN) subtype were associated with lower odds. In HER2‐positive luminal B tumors, presentation delays were associated with later stage ( p < .001). Odds of diagnostic delay were higher for younger patients and lower for those with TN tumors. Patients with more aggressive tumor subtypes were less likely to have treatment delays. Delays were not associated with DFS or OS. Conclusions: In this cohort of young patients with BC, demographic and tumor factors were associated with delays in care. It is reassuring that delays did not influence disease outcomes.
Overview
CoChat Summary
TL;DR
In a prospective cohort of 1071 women aged ≤40 years with stage 0–IV breast cancer, 14% had presentation delay, 11% had diagnostic delay, and 22% had treatment delay. Delays were not independently associated with worse disease-free or overall survival, but presentation delay was linked to later stage in HER2-positive luminal B tumors.
Key findings
- Median times were 14 days (IQR, 2–45) from first symptom to presentation, 14 days (IQR, 7–30) from presentation to diagnosis, and 41 days (IQR, 25–57) from diagnosis to treatment. Presentation delay (≥90 days) occurred in 153 patients (14%), diagnostic delay (≥90 days) in 120 (11%), and treatment delay (≥60 days) in 228 stage 0–III patients (22%).
- In multivariable models, presentation delay was associated with income <$50,000 (OR, 1.98; 95% CI, 1.22–3.13) and inversely with pregnancy at diagnosis (OR, 0.17; 95% CI, 0.01–0.80), first-degree family history of breast cancer (OR, 0.40; 95% CI, 0.17–0.80), and TNBC versus luminal A (OR, 0.29; 95% CI, 0.13–0.60). Diagnostic delay was inversely associated with age (OR per year, 0.94; 95% CI, 0.90–0.99) and TNBC versus luminal A (OR, 0.35; 95% CI, 0.16–0.70). Treatment delay was inversely associated with TNBC versus luminal A (OR, 0.26; 95% CI, 0.14–0.45) and stage III versus stage I (OR, 0.36; 95% CI, 0.19–0.63).
- Presentation delay was associated with later stage at diagnosis among HER2-positive luminal B tumors (OR for stage III/IV vs. stage I/II, 3.19; 95% CI, 1.48–6.87; p < .001). Presentation and diagnostic delays were not significantly associated with DFS or OS; treatment delay was associated with longer DFS (unadjusted HR, 0.46; 95% CI, 0.30–0.71; fully adjusted HR, 0.51; 95% CI, 0.33–0.78) and longer OS in some models, but the OS association disappeared after adjustment for treatment and stage.
Methods
- Prospective cohort: Young Women’s Breast Cancer Study, 13 academic and community sites in the United States and Canada, enrolling women aged ≤40 years at diagnosis of stage 0–IV breast cancer between 2006 and 2016; 1071 of 1297 patients were included, with baseline surveys usually completed within 6 months of diagnosis (average 4 months from diagnosis).
- Exposures: patient-reported time from first symptom to provider visit (presentation delay ≥90 days), provider visit to diagnosis (diagnostic delay ≥90 days), and medical-record diagnosis to first treatment (surgery or chemotherapy, treatment delay ≥60 days). Univariable and multivariable logistic regression with backward selection (p ≤ .05 retained) assessed factors associated with delays; Cox proportional hazards models assessed DFS and OS, stratified by tumor subtype and stage, with mediation analysis.
- Survival analyses: DFS among 928 stage I–III patients over median follow-up of 12.3 years (IQR, 10.5–15.0); OS among 984 stage I–IV patients with 157 deaths. Treatment-delay models used left truncation from first treatment and adjusted for age, subtype, surgery, chemotherapy, radiation, and stage.
Limitations
- Stated in the paper: timing from symptom onset to presentation was patient-reported, with possible misclassification; the cohort was limited in racial, ethnic, and socioeconomic diversity, consisting mostly of White, insured patients with higher-than-average incomes; active research participants may have higher health-seeking behaviors than the general population.
- Stated in the paper: small numbers within subgroups limited some analyses; lack of gene expression data may limit histologic subtype classification; results were driven by patients with luminal-like disease, leaving questions for HR-negative/HER2-positive and TNBC patients; quality-of-life outcomes were not measured.
- Evident in the text: the observational design cannot establish causality; delay thresholds (≥90 or ≥60 days) are predefined cutoffs; residual confounding and limited subgroup power may affect the null survival findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 26 Not checked · 73 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Specific delay types were not associated with survival in any individual tumor subtypes (Supporting Information S1: Table S7).”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > OS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment delay was also less common for higher grade tumors (p = .03)(Table 3).”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Treatment delay
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment delay was associated with longer DFS (unadjusted HR, 0.46; 95% CI, 0.30-0.71;p = .0003;fully adjusted HR, 0.51; 95% CI, 0.33-0.78;p = .002).”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > DFS
plainstates an associationn = 928 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Presentation delay was associated with later stage at diagnosis among those with invasive HER2-positive luminal B tumors (OR for stage III and IV vs. stage I and II, 3.19; 95% CI, 1.48-6.87;p < .001).”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Presentation delay
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results were similar when including in situ (stage 0) patients.”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > DFS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
31 more claims
Create a free account to see all 99 claims and every source verdict.
- It may state two separate claims as one. 42
- Probably not a substantial claim. 25
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Financial comfort Very comfortable 60 of 482 59 of 502 117 of 509 Less comfortable 156 of 487 1.64 (1.15-2.34).006”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Treatment delay
Reported 153 · recomputed 216
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Income ≥$50K 110 of 769 95 of 796 180 of 800 <$50K 122 of 157 1.72 (1.11-2.61).013”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Treatment delay
Reported 153 · recomputed 232
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Treatment delay
“First-degree family history of any cancer No 131 of 808 64 of 586 130 of 584”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Presentation delay
“First-degree family history of any cancer, No. (%) No 93 (8.7) Yes 918 (85.7)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Treatment delay (yes/no) b Crude 211 of 928 24 of 212 187 of 736 0.46 (0.30-0.71) .0003”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > DISCUSSION
Reported 928 · recomputed 948
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Study population
“HER2-positive luminal B (HR-positive, HER2-negative)”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Presentation delay
“HER2+ luminal B (HR+, HER2+) 206 (19.2)”
2 more findings
Create a free account to see every finding of this check.
Citations
Cites
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationTime to Surgery and Breast Cancer Survival in the United States
Bleicher, R. J., Ruth, K., Sigurdson, E. R., Beck, J. R., Ross, E., Wong, Y.-N., Patel, S. A., Boraas, M., Chang, E. I., Topham, N. S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4508 · Cited by 609
Hispanic health in the USA: a scoping review of the literature
Velasco-Mondragon, E., Jimenez, A., Palladino-Davis, A. G., Davis, D., & Escamilla-Cejudo, J. A. (2016) · Public Health Reviews · doi:10.1186/s40985-016-0043-2 · Cited by 514
Factors predicting delayed presentation of symptomatic breast cancer: a systematic review
Ramirez, A., Westcombe, A., Burgess, C., Sutton, S., Littlejohns, P., & Richards, M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02142-x · Cited by 493
Biology of breast cancer in young women
Azim, H. A., & Partridge, A. H. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0427-5 · Cited by 466
Self-citationGlobal guidelines for breast cancer screening: A systematic review
Ren, W., Chen, M., Qiao, Y., & Zhao, F. (2022) · The Breast · doi:10.1016/j.breast.2022.04.003 · Cited by 325
Delay in Breast Cancer: Implications for Stage at Diagnosis and Survival
Caplan, L. S. (2014) · Frontiers in Public Health · doi:10.3389/fpubh.2014.00087 · Cited by 320
Delays in Breast Cancer Diagnosis and Treatment by Racial/Ethnic Group
Gorin, S. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.20.2244 · Cited by 294
Smith, E. C., Ziogas, A., & Anton-Culver, H. (2013) · JAMA Surgery · doi:10.1001/jamasurg.2013.1680 · Cited by 276
Cited by
Still being checked.
Metadata
- Authors
- Zhang, B. X., Sella, T., Zheng, Y., Kirkner, G. J., Ruddy, K. J., Rosenberg, S. M., Borges, V. F., Schapira, L., Come, S. E., Peppercorn, J. M., Collins, L., Partridge, A. H., & Brantley, K. D.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic (US)
- Weill Cornell Medicine (US)
- University of Colorado Cancer Center (US)
- Stanford Medicine (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Brantley, Kristen D.
- ORCID
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2026-10-12
- Volume
- 132
- Issue
- 20
- Pages
- e70594-e70594
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W7221518840
- Cited by
- 0
- References
- 63
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- onlinelibrary.wiley.com/termsAndConditions#vor (vor)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- breast cancer, young women, delayed care, delayed presentation, delayed diagnosis, treatment delay, triple-negative breast cancer, tumor subtypes, family history of breast cancer, income, disease-free survival, overall survival
- MeSH terms
- Treatment Delay, Adult, Breast Neoplasms, Female, Humans, Neoplasm Staging, Prognosis, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Young Adult, Delayed Diagnosis, Time-to-Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delays in breast cancer presentation, diagnosis, and treatment in young women. https://app.cochat.ai/papers/10.1002/cncr.70594
- The paper
- Zhang, B. X., Sella, T., Zheng, Y., Kirkner, G. J., Ruddy, K. J., Rosenberg, S. M., Borges, V. F., Schapira, L., Come, S. E., Peppercorn, J. M., Collins, L., Partridge, A. H., & Brantley, K. D. (2026). Delays in breast cancer presentation, diagnosis, and treatment in young women. Cancer. https://doi.org/10.1002/cncr.70594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.